PD-1/PD-L1 Interaction Upregulates YAP1 Expression in HepG2 Cells Through MAPK/ERK Pathway

Effects of dihydroartemisinin combined with cisplatin on proliferation, apoptosis and migration of HepG2 cells

(2022) Qi Rao et al.   Oncology Letters

Hippo signaling instructs ectopic but not normal organ growth

(2022) W. Kowalczyk et al.   SCIENCE

Hepatocellular carcinoma

(2021) Josep M. Llovet et al.   Nature Reviews Disease Primers

Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation

(2021) Man Yu et al.   MOLECULAR CELL

Piezo1 impairs hepatocellular tumor growth via deregulation of the MAPK-mediated YAP signaling pathway

(2021) Silin Liu et al.   CELL CALCIUM

HGF/c‐MET pathway contributes to cisplatin‐mediated PD‐L1 expression in hepatocellular carcinoma

(2021) Zhan‐Sheng Zhang et al.   CELL BIOLOGY INTERNATIONAL

Anti‑malarial drug dihydroartemisinin downregulates the expression levels of CDK1 and CCNB1 in liver cancer

(2021) Liyuan Hao et al.   Oncology Letters

Dihydroartemisinin reduced lipid droplet deposition by YAP1 to promote the anti-PD-1 effect in hepatocellular carcinoma

(2021) Liyuan Hao et al.   PHYTOMEDICINE

Astragalus membranaceus–Derived Anti-Programmed Death-1 Monoclonal Antibodies with Immunomodulatory Therapeutic Effects against Tumors

(2020) Fu-Ling Chang et al.   Biomed Research International

Stiffer Matrix Accelerates Migration of Hepatocellular Carcinoma Cells through Enhanced Aerobic Glycolysis Via the MAPK-YAP Signaling

(2020) Qiu-Ping Liu et al.   Cancers

Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells

(2020) Yihe Yan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy

(2020) Xiaodong Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1

(2020) Shenghao Li et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

RalB degradation by dihydroartemisinin induces autophagy and IFI16/caspase-1 inflammasome depression in the human laryngeal squamous cell carcinoma

(2020) Xinli Shi et al.   Chinese Medicine

Dihydroartemisinin, an antimalarial drug, induces absent in melanoma 2 inflammasome activation and autophagy in human hepatocellular carcinoma HepG2215 cells

(2019) Xinli Shi et al.   PHYTOTHERAPY RESEARCH

Human mesenchymal stem cells promote tumor growth via MAPK pathway and metastasis by epithelial mesenchymal transition and integrin α5 in hepatocellular carcinoma

(2019) Jiang Chen et al.   Cell Death & Disease

Myricetin Suppresses the Propagation of Hepatocellular Carcinoma via Down-Regulating Expression of YAP

(2019) Minjing Li et al.   Cells

Tumor-Repopulating Cells Induce PD-1 Expression in CD8 + T Cells by Transferring Kynurenine and AhR Activation

(2018) Yuying Liu et al.   CANCER CELL

Functional significance of Hippo/YAP signaling for drug resistance in colorectal cancer

(2018) Ruolan Song et al.   MOLECULAR CARCINOGENESIS

Antimalarial Dihydroartemisinin Triggers Autophagy within HeLa Cells of Human Cervical Cancer through Bcl-2 Phosphorylation at Ser70

(2018) Li Wang et al.   PHYTOMEDICINE

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy

(2018) Han Yao et al.   Frontiers in Immunology

Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion

(2018) Peixin Dong et al.   Frontiers in Oncology

TNFα promotes glioblastoma A172 cell mitochondrial apoptosis via augmenting mitochondrial fission and repression of MAPK–ERK–YAP signaling pathways

(2018) Changyu Lu et al.   OncoTargets and Therapy

Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1

(2017) Hui Li et al.   HEPATOLOGY

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells

(2017) Hiro Sato et al.   Nature Communications

PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways

(2017) Shengwei Liu et al.   Oncotarget

PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance

(2017) Yan Zhang et al.   Oncotarget

PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression

(2017) Jai-Nien Tung et al.   Oncotarget

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

(2015) Sonja Kleffel et al.   CELL

The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer

(2015) S. Song et al.   CLINICAL CANCER RESEARCH

YAP activation is an early event and a potential therapeutic target in liver cancer development

(2014) Andrea Perra et al.   JOURNAL OF HEPATOLOGY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies

(2013) Li Shi et al.   Journal of Hematology & Oncology

Histone Deacetylase Inhibitors Facilitate Dihydroartemisinin-Induced Apoptosis in Liver Cancer In Vitro and In Vivo

(2012) Chris Zhiyi Zhang et al.   PLoS One

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY